Clinical efficacy and safety of Tanreqing injection combined with antibiotics versus antibiotics alone in the treatment of pulmonary infection patients after chemotherapy with lung cancer: A systematic review and meta‐analysis

Abstract

This study aimed to evaluate the efficacy and safety of Tanreqing injection (TRQi) in the treatment of pulmonary infection after chemotherapy in patients with lung cancer. Cochrane Library, PubMed, Web of Science, EMbase, CNKI, VMIS, Wan‐Fang, and CBM databases were comprehensively searched from established to March 2020. randomized controlled trials (RCTs) of TRQi were selected. The evaluation manual of Cochrane RCT was used to evaluate the methodological quality of all included studies, Stata 13.0 and Review Manager 5.3 software was used for meta‐analysis. This study is registered with PROSPERO (CRD42020175533). Eighteen RCTs with a total of 1,438 patients were met the inclusion criteria. Meta‐analysis showed that compared with antibiotics alone, TRQi plus antibiotics could significantly improve the clinical efficacy, defervescence time, lung rale disappearance time, cough disappearance time, and average hospitalization time, reduce white blood cell, C‐reactive protein, and procalcitonin levels, and adverse reactions. However, due to the small sample size and low quality of the study, more rigorous and more RCTs are needed for further verification. In conclusion, this study provides useful evidence for the efficacy and safety of TRQi combined with antibiotics in the treatment of pulmonary infection after chemotherapy with lung cancer.

Clinical Efficacy and Safety Analysis of PD-1/PD-L1 Inhibitor vs. Chemotherapy in the Treatment of Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

“…This is the first phase B clinical study to evaluate the efficacy and safety of pembrolizumab in advanced NSCLC. It was found that the effect was better in patients with elevated PD-L1 expression [34]. A total of 14 RCTS of pembrolizumab treatment for NSCLC were included in this study.…”

Clinical efficacy enhancement of a Chinese herbal injection in the treatment of mycoplasma pneumonia in children

“… [11] Its efficacy and safety have been confirmed in influenza, lung infection, and other diseases. [ 11 , 12 ] Tanreqing injection has been used in the treatment of mycoplasma pneumonia in children for many years, and it could improve the curative effect, shortening the course of disease, and reducing the side effects of Azithromycin. [13] However, there is no strict randomized controlled trial (RCT) to study the efficacy of Tanreqing injection combined with azithromycin in the treatment of MP in children.…”